HC Wainwright reaffirmed their buy rating on shares of Mind Medicine (MindMed) (NASDAQ:MNMD – Free Report) in a research ...

Mind Medicine (MindMed) (NASDAQ:MNMD – Get Free Report) had its price target decreased by investment analysts at Robert W.

Mind Medicine Inc. ( ($MNMD) ) has released its Q4 earnings. Here is a breakdown of the information Mind Medicine Inc. presented to its investors.

Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product ...

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a study approval ...

The company's earnings totaled -$34.74 million, or -$0.41 per share. This compares with -$23.86 million, or -$0.59 per share, last year. Founded in the late 1990s by Andrew Mariathasan in New York ...

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health ...

“2024 was a year of significant progress for MindMed. We successfully achieved several key milestones that have built momentum for multiple clinical readouts from our MM120 ODT Phase 3 ...

Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event. MindMed is a late-stage clinical ...

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company ...